Brigatinib
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Brigatinib: From ALK-Positive NSCLC to Gingival Fibromatosis
One-Sentence Summary
Brigatinib is an oral ALK/EGFR/ROS1 tyrosine kinase inhibitor marketed in the US, and the literature in the pack describes its use in ALK-positive non-small cell lung cancer (NSCLC). The TxGNN model predicts it may be effective for gingival fibromatosis (score 99.89%), but this is a model prediction only, with 0 clinical trials and 0 publications supporting it.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | ALK-positive NSCLC (inferred from the literature in the pack; the US license records contain no indication text) |
| Predicted New Indication | Fibromatosis, gingival |
| TxGNN Prediction Score | 99.89% |
| Evidence Level | L5 |
| US Market Status | ✓ Marketed |
| Number of NDAs | 3 records (all under NDA208772) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, brigatinib is a multi-target tyrosine kinase inhibitor (ALK, EGFR, ROS1). Its efficacy in ALK-positive NSCLC has been shown in Phase 3 trials, but no pathway linking it to gingival fibromatosis is supported by the data provided.
Gingival fibromatosis is a benign overgrowth of gum tissue, and the hereditary form has no known ALK-driven biology. The high TxGNN score reflects a knowledge-graph association only and is not backed by any trial, literature or mechanistic data. The prediction should be treated as a hypothesis, not a repurposing lead.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| NDA208772 | Alunbrig (Takeda Pharmaceuticals America, Inc.) | Tablet, film coated (oral) | Not listed in the source data |
The pack contains three identical records for this NDA, shown here once.
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted therapy (tyrosine kinase inhibitor) |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Please refer to the package insert warnings and precautions |
| Handling Protection | Please refer to the package insert warnings and precautions |
Safety Considerations
Please refer to the package insert for safety information. No warnings, contraindications or drug interaction records were available in the pack.
Literature attached to other predicted indications includes a case report of fatal tumour lysis syndrome with brigatinib (PMID 34987411), a safety signal worth noting in any repurposing plan.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has no trial or literature support (L5) and no established mechanistic link, and gingival fibromatosis is a benign condition. A systemic kinase inhibitor would need a strong risk-benefit case that is absent here.
To proceed, the following is needed:
- Package insert warnings and contraindications (a blocking data gap for safety screening)
- Mechanism of action data (from DrugBank) and any evidence linking kinase inhibition to gingival fibromatosis
- Preclinical or case-level evidence in gingival fibromatosis
Among the other predictions, brigatinib in NF2-related schwannomatosis (PMID 38904277, PMID 34264955) is a more credible lead, but it should be assessed as a separate indication.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.